CStone Pharmaceuticals (HKG:2616) booked a loss of 437 million yuan in 2025, widening from 91.2 million yuan a year earlier, according to a Thursday Hong Kong bourse filing.
Shares of the pharmaceutical firm were up nearly 18% in late Friday morning trade.
Loss per share came in at 0.31 yuan, compared with 0.07 yuan a year earlier.
Revenue fell 34% to 269.6 million yuan from 407.2 million yuan.